Bullish Options Activity on AstraZeneca plc (ADR) Surges After Better Fundamentals

 Bullish Options Activity on AstraZeneca plc (ADR) Surges After Better Fundamentals

In today’s session AstraZeneca plc (ADR) (AZN) registered an unusually high (2,291) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious AZN increase. With 2,291 contracts traded and 12484 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: AZN161118C00032500 closed last at: $0.6 or 20% up. About 559,783 shares traded hands. AstraZeneca plc (ADR) (NYSE:AZN) has risen 9.18% since March 16, 2016 and is uptrending. It has outperformed by 3.64% the S&P500.

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on November, 3. They expect $0.58 EPS, down 43.69% or $0.45 from last year’s $1.03 per share. AZN’s profit will be $1.45B for 13.32 P/E if the $0.58 EPS becomes a reality. After $0.83 actual EPS reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -30.12% negative EPS growth.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. $50 is the highest target while $32 is the lowest. The $38.40 average target is 24.27% above today’s ($30.9) stock price. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. On Wednesday, September 2 the stock rating was upgraded by HSBC to “Buy”. HBSC downgraded the shares of AZN in a report on Monday, February 8 to “Hold” rating. Bryan Garnier & Cie upgraded the shares of AZN in a report on Friday, September 18 to “Buy” rating. The firm has “Buy” rating by S&P Research given on Friday, July 31. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Hold” rating given on Monday, November 2 by Nordea. BNP Paribas downgraded AstraZeneca plc (ADR) (NYSE:AZN) on Wednesday, September 14 to “Neutral” rating. Leerink Swann maintained AstraZeneca plc (ADR) (NYSE:AZN) rating on Monday, May 2. Leerink Swann has “Market Perform” rating and $34 price target. The firm earned “Hold” rating on Tuesday, March 15 by Jefferies. The firm has “Buy” rating given on Monday, September 12 by Jefferies. Barclays Capital upgraded AstraZeneca plc (ADR) (NYSE:AZN) on Tuesday, January 19 to “Equal-Weight” rating.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of $77.49 billion. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 35.19 P/E ratio. The Firm has its activities in over 100 countries.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Another recent and important AstraZeneca plc (ADR) (NYSE:AZN) news was published by Investorplace.com which published an article titled: “3 Big Stock Charts: Chesapeake Energy Corporation (CHK), AstraZeneca plc (ADR …” on October 07, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment